The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Hope that’s not ominous
The Guardian says the former Conservative leader, Sir Iain Duncan Smith, also faces questions about his second job.
He is paid £25,000 a year as an adviser to a hand sanitiser manufacturer, Byotrol.
The paper says the company benefited from new rules recommended in May by a government taskforce chaired by Sir Iain
Read the transcript of the Solvay Q3 results Q&A released on 28 Oct. They wax lyrical on Actizone. If this is worthy of mention given their market cap of EUR 11 billion it must be potentially significant to Byotrol, market cap £24m. Royalty receipts typically lag sales by 6 months so I don’t expect this to be obvious in the next TU but the direction of travel longer term appears encouraging. I assume the directors are currently in close period under the rules therefore cannot buy shares even if they wanted to.
I think it's too little too late to be making those changes. They should have been done years ago...
Given they are already in H2, I think a profit warning is still on the cards..
From the company's results, only published in Sept:
"In the short-term, revenue from product sales in the new financial year to date has been hindered by closed venues from extended lockdowns, new competition, and an excess of inventory. However, the market does now appear to be stabilising and management now expect product sales for FY22 at a level some 10 to 20% below those for FY21: an exceptional year which was itself over 90% ahead of FY20."
https://byotrolplc.com/wp-content/uploads/2021/08/FY21-RNS-final.pdf
Yes only a matter of time IMO
Another little kick for evens ---takeover always lurking--new brooms sweep clean.
No TU then. Just the usual all resolutions passed.
AGM tomorrow. Will there be a TU, including cash in bank and any new contract wins.
Maybe the real innovation is in the delivery mechanism? As with the wet-wipe products, a major source of revenue, now that the manufacturer has been acquired by Ecolab all the innovative delivery and accreditation associated with this product has gone.
Not a mention of BYOTROL!
I wonder if this is why the SP is languishing; or is it because currently the BYOTROL website Product information page / link takes you to https://medi-mark.co.uk/products where you are greeted by the message “Not Found The requested URL /products was not found on this server.”
It’s the AGM on Wednesday morning - perhaps there will be explanations then as to the low profile the company has in the investment market and its consequential effect on the SP!
https://www.solvay.com/en/press-release/actizone-wins-first-place-innovation-award-sepawa-congress
https://www.londonstockexchange.com/news-article/BYOT/sale-of-byotrol24-in-the-americas/15156762
David Traynor, Chief Executive of Byotrol, said:
Byotrol24 is going to a very good home in Integrated Resources, and we look forward to sharing in their continuing successes in the Americas. We are particularly pleased with the new relationships IRI has been building - and that we have been helpful in securing - in the last 18 months and we expect them to accelerate progress now, particularly in the very large US markets, helping to underpin management's expectations for the current and next financial year.
Boots own brand Byot based 50ml sanitiser now 1/2 price..
Should help shift stock but at what cost?
https://www.boots.com/boots-anti-viral-hand-foam-50ml-10278907
I missed it. Probably it didnt strike a chord with people, Any views?
Yes
All blue this morning, after webinar, anyone see it?
So you're not disagreeing with them figures and totally is totally overvalued for something that earns £150 a day at Most
STTsBumbag,
"TLY Mkt Cap £63mil profir £55k. BYOT Mkt Cap £22 profit £1.1mil"
As you know, Byot were ramped on the back of sanitiser sales surging, Boots, MoS etc.
Their Mcap has halved over the past 12 months, since the MoS article, as the reality of the low global consumer sales sank in.
On the other hand TLY's mcap doubled as the reality of their business' need within the NHS and the significant growth sinks in. eg TLY's insourcing division for postponed operations only started in Oct 2019 and is growing strongly with significant demand ahead, whereas Byot had been going for years and demand is slowing.
Everyone needs healthcare, covid or not. Whereas the demand for Byot products reduce as more companies enter the market and as covid restrictions are lifted.
It's looking that way, and I hope it'll bottom out at the 3.5/4.5p band. Constant selling again today, and not a single buy yet. Who are these sellers? And why are they so desperate to take losses of this magnitude? Haven't they learnt anything? Handing over their pensions to the brokers. Makes me sad.
The exact quote was: "This view from the stt1 who has consistently knocked this stock SINCE IT WAS LESS THAN 1.5P". How odd that you left out the end of the sentence, which I have highlighted for your convenience.
TLY Mkt Cap £63mil profir £55k
BYOT Mkt Cap £22 profit £1.1mil
you do the maths STD
Tony_S
"This view from the stt1 who has consistently knocked this stock."
What do you think of the disappointing reaction to the results? You've gone quiet.
Any views?
Same here. The reaction was muted as predicted.
Where have all the rampers gone?
As I thought, no sparkles on the day of the results. One thing I've picked up with this, if the SP jumps on the news of robust results, as was the case with this stock, expect 'buy the news, sell the facts' scenario to play out. As for the great fall in SP, it's a penny stock. We are all in it for an instant gratification. With all what the board has said, expecting this to fall at least up to 3.5p before any upward move.
They are virtually at end of H1-2022 (5 weeks to go), so sales stabilising now will be too late for H1-2022 and the 'hope' is things will improve for H2-2022.
With increasing number of people being vaccinated and covid restrictions removed, I think the demand for sanitiser etc will reduce further.
"But revenue from product sales is expected to fall by 10% to 20% in financial 2022. Sales since March 31 have been hindered by venues being shut in lockdown, new competition and an excess of inventory, although the market is now stabilising."